Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -0.62% 79.50 97,974 16:15:06
Bid Price Offer Price High Price Low Price Open Price
78.00 81.00 80.00 76.50 79.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 18.77 0.71 0.42 189.3 67
Last Trade Time Trade Type Trade Size Trade Price Currency
15:26:18 O 1,000 79.44 GBX

Venture Life (VLG) Latest News

More Venture Life News
Venture Life Takeover Rumours

Venture Life (VLG) Discussions and Chat

Venture Life Forums and Chat

Date Time Title Posts
04/8/202016:58Venture Life Group plc447
04/8/202014:05ValueGrowth Investing35,039
02/4/201510:58Venture Life Group - Intro video-

Add a New Thread

Venture Life (VLG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-04 14:26:1979.441,000794.40O
2020-08-04 14:12:3578.0010,0007,800.00O
2020-08-04 14:01:0979.441,9001,509.36O
2020-08-04 13:49:3481.00177143.37O
2020-08-04 13:44:0079.321,2741,010.54O
View all Venture Life trades in real-time

Venture Life (VLG) Top Chat Posts

DateSubject
04/8/2020
09:20
Venture Life Daily Update: Venture Life Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 80p.
Venture Life Group Plc has a 4 week average price of 71p and a 12 week average price of 55.50p.
The 1 year high share price is 88.25p while the 1 year low share price is currently 22p.
There are currently 83,712,106 shares in issue and the average daily traded volume is 113,969 shares. The market capitalisation of Venture Life Group Plc is £66,551,124.27.
11/7/2020
13:29
adamb1978: Hi Homebrew re IDP: your reaction is somewhat similar to my initial reaction to their results, however reflecting on them later in the day I think their EPS this year will come in around 3p-4p. Obviously this year is somewhat anomalous (from memory last year EPS was around 7p-8p) and I'd expect them to be back in excess of 2019 earnings in 2021 however I took the view that for the share price to stay where it is requires the market to look through 2020 earnings. I fear that, despite their balance and the decent slug of director buying in the last 6-9 months, Mr Market might not be prepared to do that and the share price is more likely to hear into the 40s say rather than the 80s. As a result, I took my money off the table and will look for a lower re-entry point. I still thikn they are a good bet given operating leverage to the new products which are coming down the pipe, but that there will be the chance to get back in lower. I had bought in the high 30s in March so have made a decent return, and expect to be back in in the next 6-12 months Adam
11/6/2020
09:19
rivaldo: Nice feature on VLG on Investors' Champion (subscriber-only) - and no, there isn't a catch :o)) Https://www.investorschampion.com/channel/blog/a-reasonably-valued-healthcare-company-surely-there-must-be-a-catch "A reasonably valued healthcare company, there must be a catch! 10/06/2020 · Venture Life Group PLC (VLG) Many healthcare companies, especially with anything relating to aiding Covid-19, have benefited from a strong share price over the pandemic and it is rare to find something of seemingly reasonable value. What is the catch? Founded in 2010, Venture Life Group (LON:VLG) is an international consumer healthcare company focused on developing and manufacturing non-drug self-care products for the ageing population, which consumers can buy without prescription. The Group's manufacturing is based in Italy, where a 5,500m² factory can produce up 130,000 units a day,. producing both its own brands as well as products for others as a contract manufacturer. With over 35 years of experience, the site boasts exciting development capabilities thanks to superior laboratory facilities and knowledge of the market. The Group has 10 branded products, covering 44 global markets and 5 therapeutic areas: Oral Healthcare Proctology Dermatology Neurology Women’s healthcare etc"
23/5/2020
15:05
redartbmud: tlatsatt I don't dispute what you say, and certainly in the early stages of development odf a business it can be a help but the corollary case. 1. Renishaw 52% owned ny McMurtry and Deer. In latter years it has lost vision and drive. This may in part be to size, as it has grown and innovation has become more difficult, Also the growth has led to a size of company that needs a different management approach to build on the culture in a different way. 2. Goodwin. The last LTIP vested with a share issue equivalent to 8% of the shares in issue. Had it reached target that would have been 10% of shares. The vesting price was 10p per share, when the marlet price was c £35 per share. It could be argued that the share price was 'helped' along the way to the target. A major shareholder told me a year before that the share price would definitely hit target, when I thought it impossible. Goodwin also have control of the company. red
20/5/2020
17:49
redartbmud: tlatsatt Extreme volatility isn't too good for my constitution. Big moves, on the back of no news, especially those to the downside, do challenge one's resolve. Rsw is a good case study, the other way. The last set of results were not good, and global market conditions have deteriorated since, as the lockdown took hold. Logic says that their business to supply capital and revenue items to manufacturing industry, that is currently partially closed down or at best operating well below capacity, should result in further deterioration before the situation improves. Based on subdued profitability, the share price ought to be significantly ahead of resukts and forecasts. If that is the case, the sometimes 100p daily share price increase, on an already rising share price, is irrational. red
10/2/2020
12:11
valhamos: Not a very good piece from shares magazine. In fact it's pathetic. Lazy and inaccurate journalism to state "The update, issued at 9.57am on Monday saw the share price fall nearly 6% to 128p." Actually the update issued at 9.57am caused the share price to increase 6% from 128p to 136p For the market the update was reassuring hence the increase in the share price. Not that you would guess by the tone of the article.
28/1/2020
21:01
apad: Roger Lawson on HLMA " This morning (25/10/2019) I attended a presentation by Halma Plc (HLMA) in the Investec offices. It was given by Charles King, Head of Investor Relations and it was a very professional presentation unlike many we see. I have held shares in the company for four years and it confirmed that my choice of it as an investment was sound. But I did learn a bit more. I’ll cover some of the key points that were made. This company has strong fundamental growth drivers. It has grown both organically and by acquisition over 45 years and now has 45 companies in the portfolio which primarily operate independently. One might call it a conglomerate. It focuses on life saving technology businesses – in essence “safer, cleaner, healthier”, in global niche markets. These are often regulated markets which helps on defensibility and growth. Demographic trends help as more people who are older and fatter promote growth and higher regulatory standards also move in. There is a lot of diversity in the products. They aim for 15% growth per annum and have 6,000 staff in total. They bet strongly on “talent” to run the businesses. In essence there are many little companies all run by entrepreneurs who are left to operate as they wish. These people are paid on the basis of profit achieved in excess of the cost of capital but one requirement they look at when recruiting is that they must have “low egos”. There is only a small group of central staff handling some corporate functions. Their focus is on acquiring companies with low capital intensity and ROTIC of greater than 16% when their cost of capital is about 8%. They are very diversified internationally but see opportunities to grow more in Asia/Pacific and other developing markets. The high share price was questioned (or as one person put it: “it’s in nose bleed territory”). It’s currently on a forecast p/e of 32 according to Stockopedia which is higher than when I purchased shares in 2015 but the share price has more than doubled in that period. This company is like many high revenue/profit growth companies – they never look cheap but simply grow into their share price. However the share price has fallen back of late like a lot of highly valued technology stocks that I hold. The speaker attributed this to market trends, not management share selling. Growth companies tend to go out of fashion as economic headwinds appear. But if they stick to the business model, with the high return on capital and sensible acquisitions, I doubt they can go far wrong. In summary a useful and enlightening meeting for a company that until recently kept a low profile. But it is now in the FTSE-100 (market cap £7 billion)."
23/1/2020
08:53
redartbmud: tlatsatt Good post, explaining your thoughts and strategy behind your SOS investment. I had been musing on the broader topic myself this morning. I have come to the realisation that small cap growth companies require an additional level of micro-management compared to their larger peers: 1. They are more vunerable because of size. 2. The share price is more volatile, and often overreacts to statements, updates etc. 3. The shareholder base has a different set of expectations, and is in many respects a different set of investing individuals. That also applies, to some extent, to the institotional investment teams. It means that we have to be faster moving and more decisive, when it comes to those holdings. If I buy a big cap I can reasonably expect it to perform in a certain way, as long as management don't screw things up. Over the longer term, I can expect a reasonable return, in relation to the general market, both in dividends and capital appreciation. With a small cap that just isn't the case: Results significantly better than forecast, off into the stratosphere. Results significantly worse than forecast, off into the depths. Forward statements give the same effect. It is far more important to understand the fundamentals of the small cap. In recent times Equals, Xpd, Ztf and Vanl have all hit problems. Once they were identified, the share price immediately bombed, and has not recovered. The sensible answer was to sell at the opening bell and take the hit. They are all thrashing around, trying to address their issues, and after months we have not seen any visible improvement in trading. The share price becomes becalmed, at the bottom, with dividends often cut, but even before that act, those returns were pitiful in relation to the cost of capital. In fact there has often been a second and maybe third leg down in the share price. Rambling from Reading. red
31/12/2019
11:51
apad: Below are the collected comments on peoples 2019 Comparison entries. 2019 Reviews. janeann Key lesson for me from 2019 is how to better determine both when to sell and what are genuine btfd opportunities (and what are not). More patience to see just how far a fall is going is clearly required. And as someone else said never sell GAW. apad Abcam (ABC) This is up 30% YTD, but has been down to zero in April and October. I have lost confidence in the management and have been selling down. It is now my 11th largest holding at 2.4% of Stairway. Fever Tree (FEVR) This is now about flat on the year having been up 45%. I still have confidence and am monitoring US activity as close as I can. It is 20% of Stairway. Boo Hoo (BOO) This is the standout performer, up about 78% on the year. It is the clear leader in 'immersive brands' and has some new brand names from company failures. It will benefit from failures in the High St. so I am riding this bad baby. It is 22% of Stairway. Bioventix (BVXP) This has been up 30% in the year and is now down to breakeven. In my opinion it is the best value on the market and I am buying more at every opportunity. It is PI driven and they are impatient. I believe that the hs-troponin income will increase at a much more rapid rate than the forecasts. Renishaw (RSW) This company is dependent on the global cycle and I knew this but ignored it. It is down about 7% having been down about 20%. It does this when it doesn't deserve it. I intend to top-slice before the next results. Valhamos D4T4 - up 9% having been up 46% at one stage; long term growth story seems to be intact but this is masked in the short term by the increasing switch from upfront licence sales to the SaaS model. Still lowly rated (P/E 14) and will include in next year’s comparison. 7% of portfolio. XPP - will also include again; 37% increase. Recovery from lows at beginning of the year, fears of impact of tariffs and decline in semi conductor industry have eased. Semi-conductor manufacture is building up again with 5G - see recent increases in SWKS and LRCX which I also hold. Largest shareholding at 8% of portfolio. CHH - 94% increase, quietly performs without attracting much interest. The ADVFN board has had 3 posts in last 6 months - my sort of share. GHT - Recovery from last year’s profit warning; today’s news should dispel doubts about current year’s performance; up 69% SDI - up 117%; a good track record up to now of extracting value from acquisitions. Can it last? Will it be another JDG? After a good year I have recently taken out my original stake and will let the rest run. lomax99 BUR - Down c 57% YTD 2019, IMO mis-priced following short attack, looking forward to 2020 US listing. FUTR - A gain of over 200% YTD 2019, expect the ascent to continue. Looking forward to transformation of TI Media pending acquisition. HL. - Up c 6% YTD 2019. Leading D2C platform, long term structural growth story, excellent margins. Active Savings gaining traction. The W effect has been setback. BVXP - Expect troponin to start to gain traction, excellent margins. EYE - Digital promotions, starting to gain traction. Significant market opportunity, not without risk. BUR was painful, FUTR more than compensated for that. Woodford impacted HL. and didn’t particularly help BUR. ACSO and FFX/EQLS were disappointing, sold both, neither holding was significant. Lost money on ACSO, and a reduced profit on EQLS. Should have carried CVSG choice over from the previous year, still hold. attrader XPD - Transport and logistics group acquiring smaller firms in easter Europe. ROI on acquired businesses is around 10% so it might not be a great investment in the long run... It tanked due to missteps and PIs loosing confidence in management. I revisited my thesis and concluded I do not understand the business. Luckily exited the position before disaster struck. GLE - Low cost house builder aiming to double unit production by 2022. It pays decent dividend. Business performance is highly cyclical - needs constant supply of land along with housing demand and availability of mortgages... It is a capital intensive cyclical business. However, ROC is high and chronic shortage of affordable housing in UK will support their profits. Up roughly 20% YTD. IGG - Spread betting business diversifying into SIPP and Index funds. Government is increasing regulation to protect novice punters... Up roughly 15% YTD. I sold out out after final year results. Majority of their spread betting customers loose money. Churn is high. Regulations ever more strict. I am unable to visualise their future prospects so not invested any more. BUR - Litigation finance player investing ever increasing sums of cash for high returns. Low barriers to entry will invite larger players reducing ROI for future investments... It is down 50% YTD after MW highlighted accounting practises and lack of trust in management. I sold out after FY result citing similar issues here. NPSNY (Naspers ADR) - South African tech investor with large stake in Tencent along with other emerging market tech investments. Trading at significant discount to NAV. A crash in tech valuations can dent their performance in coming years... Naspers demerged Prosus & Multichoice. Adjusting for demergers, YTD gain is 0%. I have sold out as expected event has passed. Lauders AMER - Colombian oiler that has taken a share price hit this year but recent news has been excellent and there has been strong director buying. I believe that things will get better in 2019 providing the oil price holds of course. On 15 November 2019 a recommended cash offer for Amerisur Resources plc ("Amerisur") by Geopark Limited ("Geopark") was made at 19.21p. This was a disappointing offer and the 15.88% gain I made on the starting price of 2019 could have been oh so much better! ARS - A junior (puppy) copper play. Again taken a major share price hit recently but if good news comes on drilling, partnering and the Cu price strengthens then the appetite could return quickly. My worst performer of 2019 at a shocking -47.50% due to a poor BOD and the weak Cu price. Things just didn't come together and the share price was very volatile. Didn't pick again but still hold all my shares and would like to top-up but the BOD are not in my good books and hence I have decided against adding any more. If Cu takes-off in 2020 and the BOD finally get their act together things may turnaround significantly for the best. Too much of a gamble for me to keep in the comparison although I hope it all does come good for obvious reasons! HCM - News due before the end of the year so could strengthen significantly if positive. However, it is Chinese and if news is not so good on the trials and alliances it could take a major hit. If Trump continues his Chinese battles then again could be impacted. The 8.17% gain on the start of the year share price could also have been so much better if it were not for the parent company wanting to place a load of shares at quite a discount and for perhaps the anti-China sentiment that gripped the markets after the US levied a whole series of penalties on Chinese companies affecting sentiment in all things Chinese. I am hopeful that 2020 will be a much better year in this respect and HCM will respond accordingly. Hence my retention of it in the comparison for 2020. SIA - One of my dogs! Not a puppy but a badly behaving large one. I think the trainer will have sorted it out by new year and its behaviour will improve. Recent news about its Egyptian acquisition that will hopefully be completed in the first half of 2019 will producing some drilling and get the news flowing again. There may be other M&A activity involving the company in the year. What a dog it remains! Every dog has its day though and 2020 may be it for SIA. I don't want to be disappointed again though so while I still hold in physical shares I will ditch it from the comparison. -24.29 for 2019! 2020 has to be better and it really needs to be in order to re-rate the shares. TXP - Another oiler (oil had better perform well in 2019!) based in Trinidad and Tobago. News due before year end again but some important drilling will be undertaken in 2019 with the potential to significantly change the MKT Cap of the company. Should be exciting! My best performer over the year as the important drilling proved to be a success. More to come on this one I believe and hence I am retaining it among my comparisons for 2020. A gain of 78.40% in 2019 and would hope for at least the same in 2020! Cragside Thanks to all of the contributions during the year which have been interesting, thought provoking, and good to have different points of view. Between Christmas and New Year is a good time for reflection, particularly on what happens to the best laid plans so here goes HUR - Could be a significant year ahead with a lot of action in the North Sea. Fully funded, no debt. Well there was some action and successful hooking up, but the exploratory drilling showed resources not as good expected. Still plenty to go for here though. I was frustrated with the price action not reflecting progress during the year so sold out at 44p in July. Have no regrets yet. SQZ another oiler in the North Sea. No debt, and recent big deal with BP. Difficult to calculate projections but very low PE of 2 approx. Like most oilers, the share price this year is dependent upon the price of oil generally. A year of consolidation for SQZ. Disappointed that a dividend was not started in the year, and beginning to wonder where shareholders fit into things. Sold out in July again at £1.21. Maybe I did not give it a chance. Time will tell. ARE - Fairly recent float in the specialist area of hiring out gear for events particularly large sporting occasions eg Wimbledon, Open golf. Had problems with US tax authorities last year from a company acquired, but a settlement was reached. Expecting a steady if not spectacular performance. What a disaster this was. Management have no idea buying up loss making companies, when they should be concentrating on making a profit on the existing business and growing organically. Maybe a typical over hyped float followed by the inevitable crash. Bailed out on 17/1/19 at 40p. Lost quickly, and badly, but would have been much worse if I had held on. VLE - Must be worth the current share price based on cash alone. Not many new investment as of late, except share buybacks. Management has a good track in turning around companies. Very little went on with this company during the year. 1 sale, no new investments, good special dividend paid out. Steady if unspectacular performer. ARC - Good performer in 2018, and no reason to sell. Small well managed operation with apparently low customer turnover. This is proving to be a well managed outfit in a niche market with growth albeit the share price can be erratic at times. Often mentioned on this board So overall not a good average year for the 5 selected, especially ARE.
29/12/2019
15:39
cragside: Thanks to all of the contributions during the year which have been interesting, thought provoking, and good to have different points of view. Between Christmas and New Year is a good time for reflection, particularly on what happens to the best laid plans so here goes: HUR - Could be a significant year ahead with a lot of action in the North Sea. Fully funded, no debt. Well there was some action and successful hooking up, but the exploratory drilling showed resources not as good expected. Still plenty to go for here though. I was frustrated with the price action not reflecting progress during the year so sold out at 44p in July. Have no regrets yet. SQZ another oiler in the North Sea. No debt, and recent big deal with BP. Difficult to calculate projections but very low PE of 2 approx. Like most oilers, the share price this year is dependent upon the price of oil generally. A year of consolidation for SQZ. Disappointed that a dividend was not started in the year, and beginning to wonder where shareholders fit into things. Sold out in July again at £1.21. Maybe I did not give it a chance. Time will tell. ARE - Fairly recent float in the specialist area of hiring out gear for events particularly large sporting occasions eg Wimbledon, Open golf. Had problems with US tax authorities last year from a company acquired, but a settlement was reached. Expecting a steady if not spectacular performance. What a disaster this was. Management have no idea buying up loss making companies, when they should be concentrating on making a profit on the existing business and growing organically. Maybe a typical over hyped float followed by the inevitable crash. Bailed out on 17/1/19 at 40p. Lost quickly, and badly, but would have been much worse if I had held on. VLE - Must be worth the current share price based on cash alone. Not many new investment as of late, except share buybacks. Management has a good track in turning around companies. Very little went on with this company during the year. 1 sale, no new investments, good special dividend paid out. Steady if unspectacular performer. ARC - Good performer in 2018, and no reason to sell. Small well managed operation with apparently low customer turnover. This is proving to be a well managed outfit in a niche market with growth albeit the share price can be erratic at times. Often mentioned on this board So overall not a good average year for the 5 selected, especially ARE. Will set out the 5 for 2020 in the next couple of days.
29/12/2019
03:56
lauders: Perhaps these five "conviction" picks for 2020 can be added to the comparison out of interest too? Http://www.alignresearch.co.uk/gaming-realms/3248/ As for my performance in the last comparison: AMER - Colombian oiler that has taken a share price hit this year but recent news has been excellent and there has been strong director buying. I believe that things will get better in 2019 providing the oil price holds of course. On 15 November 2019 a recommended cash offer for Amerisur Resources plc ("Amerisur") by Geopark Limited ("Geopark") was made at 19.21p. This was a disappointing offer and the 15.88% gain I made on the starting price of 2019 could have been oh so much better! ARS - A junior (puppy) copper play. Again taken a major share price hit recently but if good news comes on drilling, partnering and the Cu price strengthens then the appetite could return quickly. My worst performer of 2019 at a shocking -47.50% due to a poor BOD and the weak Cu price. Things just didn't come together and the share price was very volatile. Didn't pick again but still hold all my shares and would like to top-up but the BOD are not in my good books and hence I have decided against adding any more. If Cu takes-off in 2020 and the BOD finally get their act together things may turnaround significantly for the best. Too much of a gamble for me to keep in the comparison although I hope it all does come good for obvious reasons! HCM - News due before the end of the year so could strengthen significantly if positive. However, it is Chinese and if news is not so good on the trials and alliances it could take a major hit. If Trump continues his Chinese battles then again could be impacted. The 8.17% gain on the start of the year share price could also have been so much better if it were not for the parent company wanting to place a load of shares at quite a discount and for perhaps the anti-China sentiment that gripped the markets after the US levied a whole series of penalties on Chinese companies affecting sentiment in all things Chinese. I am hopeful that 2020 will be a much better year in this respect and HCM will respond accordingly. Hence my retention of it in the comparison for 2020. SIA - One of my dogs! Not a puppy but a badly behaving large one. I think the trainer will have sorted it out by new year and its behaviour will improve. Recent news about its Egyptian acquisition that will hopefully be completed in the first half of 2019 will producing some drilling and get the news flowing again. There may be other M&A activity involving the company in the year. What a dog it remains! Every dog has its day though and 2020 may be it for SIA. I don't want to be disappointed again though so while I still hold in physical shares I will ditch it from the comparison. -24.29 for 2019! 2020 has to be better and it really needs to be in order to re-rate the shares. TXP - Another oiler (oil had better perform well in 2019!) based in Trinidad and Tobago. News due before year end again but some important drilling will be undertaken in 2019 with the potential to significantly change the MKT Cap of the company. Should be exciting! My best performer over the year as the important drilling proved to be a success. More to come on this one I believe and hence I am retaining it among my comparisons for 2020. A gain of 78.40% in 2019 and would hope for at least the same in 2020!
Venture Life share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200805 03:41:44